Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million
Reuters2026/08/06 12:32- Sonoma Pharmaceuticals posted a net loss of USD 330,000 for the quarter ended June 30, 2026, narrowing from USD 1.24 million.
- Revenue rose 60% to USD 6.41 million, led by the United States where revenue more than doubled to USD 2.43 million.
- Gross profit climbed 76% to USD 2.58 million; gross margin widened 4 percentage points to 40% on manufacturing improvements and customer mix.
- Cash and cash equivalents increased to USD 5.34 million at June 30 from USD 2.4 million at March 31, helped by USD 3.45 million in financing cash flow.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI's Next Big Winners Emerging? PIMCO Avoids U.S. Stock Giants, Makes Heavy Bets on Asian "Pick-and-Shovel" Companies
PIMCO fund manager Sharef believes that as capital expenditures in AI continue to shift towards data centers and infrastructure, Asian supply chain companies—with their lower valuations and stronger profit growth—stand to benefit more directly from the AI construction cycle compared to the highly valued and increasingly indebted US tech giants. As a result, he underweights most large US tech stocks and instead is heavily invested in "picks-and-shovels" companies such as Samsung Electronics, SK Hynix, and TSMC.
Meme Express: DogWifHat market cap on BSC surpasses $700,000
How to Make Money With Crypto? Apeing’s 1000x Crypto Hype Hits the Final Stretch Before September 8th
Crypto prices
More
